I just heard back from Onyx Pharmaceuticals’ Director of Communications, Lori Murray, with an answer to yesterday’s question from our reader in India:
We have a Phase 3 trial in Europe/Eastern Europe evaluating CFZ in relapsed/refractory to support a European filing. Unfortunately, we don’t have anything currently enrolling in India in the relapsed/refractory setting.
It is stories like these that keep us focused on getting this drug to patients as quickly as possible. I wish I had better news for them.
Me, too! Good luck to you and your wife, JP!
Feel good and keep smiling! Pat